Shaping the Future
of Respiratory Care

We are a medtech startup deeply committed to delivering top-notch cutting-edge respiratory care technology that pushes the boundaries of innovation to the future of healthcare

The World’s First Holistic
AI-Powered Pulmonology
Care System

EMILY.AI uses more than 40 parameters continuously monitored to customize long-term oxygen therapy in real-time, independent of the ongoing patient’s needs, the type of disease, localization, condition, or situation.

Our latest functional prototype has surpassed other automated closed-loop devices (maximum achieved 81% of the time in secure SpO2) by obtaining an 87% of the time secure SpO2.

Our explainable neural network algorithm applied to the upcoming version is expected to exceed 95% of the time in the secure SpO2 range.

Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes irreversible obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus (sputum) production and wheezing. It’s the most widespread respiratory disease, and the following information outlines its impact figures

+ 0 M
patients worldwide
0 rd
leading cause of death
0 th
most disabling condition
+ 0 %
yearly increase
+ 0 M
patients receive LTOT worldwide o globally (Long-Term Oxygen Therapy)
+ 380 M
patients worldwide
3 rd
leading cause of death
5 th
most disabling condition
+ 12 %
yearly increase
+ 40 M
patients receive LTOT worldwide o globally (Long-Term Oxygen Therapy)
0 K

Average annual direct cost of COPD patients in Europe requiring Long-Term Oxygen Therapy (LTOT)

+ 0 %

  Estimated total direct costs savings by using EMILY.AI

33 K

Average annual direct cost of COPD patients in Europe requiring Long-Term Oxygen Therapy (LTOT)

+ 48 %

  Estimated total direct costs savings by using EMILY.AI

Oxygen therapy today
is based on a
100-year-old method

Patients who receive long-term oxygen therapy (LTOT) spend almost 60% of their time with impaired oxygen levels. Minimum 15 hours/day. This inadequate oxygen flow can lead to episodes of hypoxemia or hyperoxemia, that can have life threatening consequences:

Inadequate Oxygenation

Respiratory Distress

Organ Dysfunction

Exacerbation of Respiratory Conditions

Cardiac Strain

Delayed Recovery, Complications & Hospitalizations

EMILY, our dedicated pulmonologist powered by AI, is available 24/7 to evaluate your data and predict exacerbations up to 72 hours in advance.

Will help you manage your «disease» better than no one system available in the market

EMILY, our dedicated pulmonologist powered by AI, is available 24/7 to evaluate your data and predict exacerbations up to 72 hours in advance.

Will help you manage your «disease» better than no one system available in the market

How it works

Our team of top-notch healthcare, business, and technology experts is dedicated to upholding the highest standards in our field.

EXECUTIVE TEAM

Daniel Oliva

CEO & Founder
ExDeputy Director at Kosmos BTW others Multinational companies and entrepreneurship projects

Rodolfo Campos

Partner & CTO
Deep background in Software Engineering and Entrepreneurship

Sara Heili, MD
Head Pulmonolgy of Fundación Jiménez Dïaz

Chief Medical Officer
4 times consecutive years Forbes Best 100 Doctors

Alba Naya, MD
Pulmonologist Fundación Jiménez Dïaz

Researcher

ADVISORS

Raimon Belenes, MD

Board Member, Partner & Promoter
A Benchmark in C-Level Health Management

 

Javier Viaña, PhD

Researcher in AI at MIT & Advisor
Best Paper in the US
Worked for NASA and THALES

Dr. Antoni Torres

Ramon Gomis, MD, PhD

Board Member & Research Strategy Advisor
exCEO at IDIBAPS
Board Member in Reig Jofre
Creu Sant Jordi Awarded

Supported by

Do you want to know more?